SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Authors:
- Gilbert Z. MurimwaGMGilbert Z. Murimwa
- Natalie E. WilliamsNWNatalie E. Williams
- Dina AlzhanovaDADina Alzhanova
- Amir MohammadiAMAmir Mohammadi
- Jill M. WestcottJWJill M. Westcott
- Francisca BeatoFBFrancisca Beato
- Ruifan DaiRDRuifan Dai
- Luis NiveloLNLuis Nivelo
- Francesca RossiFRFrancesca Rossi
- Henry K. FlemingHFHenry K. Fleming
- Alexandra F. TassielliATAlexandra F. Tassielli
- Zeynep YazganZYZeynep Yazgan
Open Access
- 29 May 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (16) , 2987-2996
Abstract
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the therapies have gained FDA approval. Nevertheless, TGFβ blockade may hold promise for a subset of cancers with nonfunctional TGFβ signaling. More than 25% of pancreatic cancers carry mutations in SMAD4, a key component of canonical TGFβ signaling. In this study, we investigated the potential for stratifying patients based on SMAD4 mutational status to identify tumors susceptible to TGFβ inhibition. Analysis of SMAD4 expression in human pancreatic tumors revealed that SMAD4 mutation or loss is associated with worse disease-free survival. Intriguingly, intratumoral SMAD4 expression displayed heterogeneity among human pancreatic cancer samples. SMAD4-deficient genetically engineered mouse models and orthotopic SMAD4 knockout tumor models exhibited reduced survival, increased metastasis, and alterations in the tumor microenvironment compared with SMAD4 wild-type controls, consistent with gene and protein expression changes in the absence of functional SMAD4. Importantly, treating mice bearing SMAD4-deficient tumors with a blocking TGFβ antibody reduced tumor weight and improved survival. These findings suggest that genomic stratification by TGFβ axis alterations, such as SMAD4 mutations, may be a promising approach to identifying patients likely to benefit from a TGFβ inhibitor. Significance: Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.Keywords
All Related Versions
Funding Information
- Center for Cancer Research (R01CA243577)
- Center for Cancer Research (R01CA243577-S1)
- Burroughs Wellcome Fund
- Effie Marie Cain Fellowship
This publication has 25 references indexed in Scilit:
- The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical SignificanceJournal of Clinical Medicine, 2017
- Genomic analyses identify molecular subtypes of pancreatic cancerNature, 2016
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature Genetics, 2015
- Neutralizing Murine TGFβR2 Promotes a Differentiated Tumor Cell Phenotype and Inhibits Pancreatic Cancer MetastasisCancer Research, 2014
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- TGF-β and αvβ6 Integrin Act in a Common Pathway to Suppress Pancreatic Cancer ProgressionCancer Research, 2012
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapyNature Medicine, 2011
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancerGenes & Development, 2006
- Mechanisms of TGF-β Signaling from Cell Membrane to the NucleusCell, 2003